High-concentration liposome processing method

• US 4,781,871 A
• Filed: 09/18/1986
• Issued: 11/01/1988
• Est. Priority Date: 09/18/1986
• Status: Expired due to Term

• Current Assignee: Liposome Technology, Inc.
• Original Assignee: Liposome Technology, Inc.
• Inventors: Martin, Francis J., West, Glenn III
• Primary Examiner(s): Lovering, Richard D.
• Application Number:
  US06/909,122
• Time in Patent Office: 775 Days
• Field of Search: 264/4.3, 264/4.6, 424/450, 436/829
• US Class Current: 264/4.3
• CPC Class Codes: A61K 9/1277 Processes for preparing; Proliposomes
• CPC Class Codes: Y10S 436/829 Liposomes, e.g. encapsulation

Abstract

A method of preparing a concentrated liposome suspension having a lipid concentration of greater than about 250 μm/ml and liposome sizes no greater than about 0.4 microns. A solution of vesicle-forming lipids in a chlorofluorocarbon solvent is injected under selected conditions into an aqueous medium, with continual solvent removal. During the lipid injection and solvent-removal steps, the liposomes formed in the aqueous medium are extruded through a membrane, to reduce liposome sizes to less than about 0.6 microns. The lipid injection, solvent removal, and extrusion steps are continued until a lipid concentration of at least about 150 μm/ml is reached.

Claims

1. A method of preparing a suspension of liposomes having a lipid concentration of greater than about 300 μ

m/ml, and liposomes sizes no greater than about 0.4 microns, said method comprising

dissolving liposomes-forming lipids in a chlorofluorocarbon solvent, to form a lipid-in-solvent solution,

injecting the lipid solution, in liquid form, into an aqueous medium, under pressure and temperature conditions at which lipid frothing is largely prevented, and at an injection rate that produces predominantly oligolamellar liposomes,

during said injecting, removing injected chlorofluorocarbon solvent from the aqueous medium at substantially the same rate that it is introduced into the medium,

also during said injecting, extruding liposomes formed in the aqueous medium to reduce the sizes of the largest liposomes to less than about 0.4 microns, and

continuing said injecting, removing and extruding until the lipid concentration in the aqueous medium is at least about 300 μ

m/ml.

2. The method of claim 1, wherein said lipids are dissolved in "Freon 11", at a concentration of between about 100-700 μ

m/ml.

3. The method of claim 2, wherein the lipid solvent also includes "Freon 21".

4. The method of claim 1, wherein the lipid solution has a lipid concentration of between about 250-700 μ

m/ml, and the lipid solution is injected into the aqueous medium, at an injection rate of about 0.5-2 ml lipid solution per 100 ml aqueous medium per minute.

5. The method of claim 1, wherein the liposomes are extruded through a polycarbonate membrane having a selected pore size of between 0.1-0.4 microns.

6. The method of claim 1, wherein the liposomes are extruded through an asymmetric ceramic filter having a pore size of about 1 micron.

7. The method of claim 1, for use in producing liposomes containing an entrapped lipophilic compound. wherein the compound is dissolved in the lipid solution.

8. The method of claim 7, wherein the compound is selected from the group consisting of protaglandins, amphotericin B, progesterone, isosorbide dinitrixe, testosterone, nitroglycerin, estradiol, cortisone, dexamethasome and related esters, and betamethasone valerate.

9. The method of claim 1, for use in preparing liposomes containing an encapsulated water-soluble compound selected from the group consisting of calcitonin, atriopeptin, α

-1 antitrypsin, interferon, oxytocin, vasopressin, insulin, interleukin-2, superoxide dismutase tissue plasminogen activator plasma factor 8, epidermal growth factor, tumor necrosis factor. lung surfactant protein, and lipocortin, wherein the compound is originally dissolved in the aqueous medium.

10. The method of claim 9, wherein the final concentration of lipids in the suspension is between about 400-600 μ

mole/ml, and at least about 50% of the compound is in liposome-encapsulated form.

11. The method of claim 1 for use in preparing liposomes containing a water-soluble compound which is soluble in a chlorofluorocarbon solvent also containing a solvent which is co-miscible with water and chlorofluorocatbon. wherein the compound is originally dissolved in the lipid solvent.

12. The method of claim 11, wherein the compound is propranolol, and the chlorofluorocarbon solvent contains a volume percentage of ethanol needed to solubilize the compound in the solvent.

13. The method of claim 1, for use in forming liposomes which are predominantly free of liposomes less than about 0.1 micron in size, wherein the suspension is formed in a reactor which is being fed continuously with both lipid solution and aqueous medium and which further includes subjecting the suspension to diaf-iltration during said infusing, to form a filtrate containing liposomes which are predominantly less than about 0.1 microns in size, nd a retentate containing liposomes predominantly above about 0.1 microns in size, and in using the lipid solution into the filtrate.

14. The method of claim 1, which further includes sterilizing the liposome injection by filtration through a sterilization filter.